Eiger BioPharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes repurposed clinical agents as well as preclinical new chemical entities (NCEs) from its discovery research shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
